Mouse Anti-ERBB2 Recombinant Antibody (clone 2D9) (CAT#: HPAB-2835LY)

Figure 1 Epitope mapping of anti-HER2 antibodies using indirect immunofluorescence assay.

Trastuzumab, CB11: a monoclonal antibody recognizing an epitope at intracellular domain of HER2 that was used as a positive control for expression of transfected plasmids.

Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M., & Yagci, T. (2012). Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC cancer, 12(1), 450.

Figure 2 In vitro molecular responses of SK-BR-3 cell to anti-HER2 antibody.

Untreated cells were incubated in a parallel experiment in the absence of any treatment.

Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M., & Yagci, T. (2012). Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC cancer, 12(1), 450.

Figure 3 Binding affinities of anti-HER2 antibodies.

HER2 ECD ELISA assay showing the binding strengths of five monoclonal antibodies. HER2 ECD-coated plates were incubated with increasing concentrations of anti-HER2 antibodies, followed by alkaline phosphatase-conjugated anti-mouse IgG antibodies.

Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M., & Yagci, T. (2012). Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC cancer, 12(1), 450.

Figure 4 Flow cytometric analysis of antibody binding to high HER2-expressing BT-474.

Fixed single-cell suspensions were incubated with anti-HER2 antibodies, followed by Alexa-488-conjugated secondary antibodies and fluorescence intensities were measured using flow cytometry.

Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M., & Yagci, T. (2012). Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC cancer, 12(1), 450.

Figure 5 Anti-HER2 antibodies exhibit enhanced anti-growth effect in the presence of tumor necrosis factor-α in SK-BR-3 cells.

SK-BR-3 cells were plated onto 96-well plates and incubated at 37°C with 5% CO2. After 2 h of incubation, antibodies (0–10 μg/ml) were added, and cells were incubated for 6 days.

Ceran, C., Cokol, M., Cingoz, S., Tasan, I., Ozturk, M., & Yagci, T. (2012). Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC cancer, 12(1), 450.